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HObjective: This study compared clinical outcomes of patients receiving CryoValve SG decellularized pulmonary
valves with those of patients receiving conventionally processed CryoValve pulmonary valves.
Methods: All consecutive patients undergoing Ross procedures and right ventricular outflow tract reconstruc-
tions with SG valves at 7 institutions (February 2000–November 2005) were assessed retrospectively (193
Ross procedures, 149 right ventricular outflow tract reconstructions). Patient, procedural, and outcome data
were compared with those from 1246 conventional implants (665 Ross procedures, 581 right ventricular outflow
tract reconstructions). Hemodynamic function was assessed at latest follow-up.
Results: Follow-up was complete for 99% in SG group and 94% in conventional group, with mean follow-ups of
4.0 years (range, 0–6.7 years) for SG and 3.7 years (range, 0–6.7 years) for conventional. Five-year cumulative
survivals and freedoms from adverse events were comparable between SG and conventional valves. Among pa-
tients undergoing Ross procedures, peak gradient at last follow-up was lower with SG valves (P< .01); no dif-
ference was observed in the right ventricular outflow tract reconstruction population. Pulmonary insufficiency
was significantly reduced with SG valves in patients undergoing both Ross procedures (P< .01) and right ven-
tricular outflow tract reconstructions (P<.01). Valve type was not a significant predictor of valve-related failure
in propensity-adjusted analysis of either procedure.
Conclusions: CryoValve SG decellularized pulmonary valves have acceptable clinical outcomes and favorably
compare with conventionally processed valves. Improved hemodynamic function observed with SG valves could
signify improved long-term outcomes and may be due to the decreased antigenicity of these valves. (J Thorac
Cardiovasc Surg 2010;139:339-48)Earn CME credits at
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The Journal of Thoracic and Calesions and in replacement of the native pulmonary valve
during the Ross procedure (pulmonary autograft). Clinical
results from the use of cryopreserved allograft heart valves
demonstrate excellent hemodynamic performance, resis-
tance to infection, and good durability, especially in the
Ross operation.1-7 Conventionally processed cryopreserved
allografts have been shown to stimulate donor-specific hu-
moral and cellular immune responses, however, which may
decrease the durability of conventional cryopreserved
valves, especially in younger patients.8-12 The CryoValve
SG pulmonary allograft valve (SGPV; CryoLife, Inc, Kenne-
saw, Ga) was developed to reduce the antigenic donor cells
that remain after conventional valve processing methods.
The SGPV was introduced into clinical use in 2000. Early
clinical reports have demonstrated a significant reduction
in the immunologic response by recipients of SGPVs asmea-
sured by panel-reactive antibody levels relative to recipients
of conventional cryopreserved allograft valves.13-16
This study evaluated clinical and echocardiographic out-
comes of patients receiving SGPVs for either the Ross
procedure or right ventricular outflow tract (RVOT)
reconstruction. Results from patients with SGPVs were
compared with results from the conventionally processedrdiovascular Surgery c Volume 139, Number 2 339
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
LOR ¼ linearized occurrence rate
RVOT ¼ right ventricular outflow tract
SGPV ¼ CryoValve SGpulmonary allograft valve
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Dcryopreserved CryoValve pulmonary allograft valve (Cryo-
Life). Analyses included propensity-adjusted evaluation of
valve-related failure to assess the effect of the SynerGraft
process of decellularization (CryoLife) on allograft valve
durability.MATERIALS AND METHODS
Participating Institutions and Patient Population
This was a retrospective, nonrandomized, multicenter cohort analysis
involving 7 implanting institutions in the United States. Institutional review
board approval for the study was obtained at each institution. All consecu-
tive patients in whom SGPVs were implanted during the Ross procedure or
RVOT reconstruction (February 2000–November 2005) were included in
the study. Patients who did not consent (n ¼ 2) were excluded, resulting
in 342 patients subjected to follow-up. Of the 342 patients included in the
study, 193 received the SGPV during a Ross operation and 149 during
RVOT reconstruction. The participating institutions and corresponding pa-
tient enrollment were as follows: University of Oklahoma Health Sciences
Center, Oklahoma City, Okla (n¼ 133); Indiana University School of Med-
icine Hospital, Indianapolis, Ind (n¼ 41); The Children’s Hospital Heart In-
stitute, Denver, Colo (n ¼ 51); Children’s Hospital of Wisconsin,
Milwaukee, Wis (n ¼ 43); Washington University, St Louis, Mo (n ¼ 34);
Methodist Hospital of Indiana, Indianapolis, Ind (n¼ 20); and LDSHospital,
Salt Lake City, Utah (n ¼ 20). The 342 study patients constituted the Cryo-
Valve SG pulmonary human heart valve 510(k) clinical study (K033484),
funded by CryoLife.
Control Data
To compare outcomes of patients receiving SGPVswith those of patients
receiving conventional valves, similar data from 1246 conventionally pro-
cessed CryoValve pulmonary valves (1985–2006) used for Ross procedures
and RVOT reconstructions were obtained from the CryoLife Clinical Reg-
istry (CryoLife, data on file). This registry includes CryoValve data from 7
institutions including 4 (Oklahoma, Denver, Milwaukee, and Salt Lake
City) that also participated in this SGPV data collection. The follow-up pe-
riod for the conventional valve control data was truncated to that available
for the SGPV cohort (6.7 years) to aid in comparison.
Preoperative Diagnoses and Operative Procedures
The overall patient population was divided by operative procedure, Ross
procedure or RVOT reconstruction.Within those subgroups, general patient
characteristics, preoperative etiology, and previous valve or conduit re-
placements are shown in Table 1. Included in the RVOT reconstruction sub-
group were 81 partial orthotopic procedures, 44 extracardiac procedures, 16
orthotopic reconstructions (all Ross reimplants), and 8 other RVOT recon-
structions.
Data Collection Methods
Patient follow-up data were obtained from hospital and clinic records as
well as direct patient contact as necessary. In cases of direct patient follow-
up, the patients were queried regarding their current state of health and asked340 The Journal of Thoracic and Cardiovascular Surgto provide contact information for their current treating physicians. The
treating physicians were then contacted to provide the patients’ recent clin-
ical data. All attempts were made to collect recent follow-up, including
echocardiographic data fromwithin 1 year of study initiation. Demographic,
operative, perioperative, and adverse event data were collected for each
patient. Operative and perioperative data included the following: general
risk factors, history of cardiac surgery including type of previous valve re-
placement, operative diagnosis, coexisting cardiac conditions, and concom-
itant procedures. Adverse events collected included mortality, valve-related
mortality, explantation, other cardiac reintervention, endocarditis, thrombo-
sis, thromboembolism, nonstructural dysfunction, and bleeding.
Hemodynamic data (peak ormean transvalvular gradient and valvular in-
sufficiency) from echocardiographic or cardiac catheterization reports were
collected preoperatively, at discharge, and as available during the follow-up
period. Pulmonary regurgitation was graded semiquantitatively on a 5-point
scale as none (0) to severe (4þ). All data were collected with uniform case
report forms.
Definitions
Early events were defined as those occurring during the same hospitali-
zation or within 30 days of implantation. All other events were considered
late. Valve-related events were documented according to the guidelines for
reporting mortality andmorbidity after cardiac valve interventions.17 Valve-
related failure was defined as valve reintervention, valve explantation, or
clinical evidence of valve-related mortality.
Valve Processing
All valves for the study were processed by CryoLife, either with the Syn-
erGraft process18 or with the conventional processing methodology for Cry-
oValve (control data).19 The SynerGraft process uses hypotonic lysis and
nuclease digestion of the cellular elements, along with repeated washing
of the tissue. The process removes more than 99% of the cells and nucleic
acids from all elements of the tissue matrix. The valves are subsequently
cryopreserved in a manner identical to that used for the conventional Cryo-
Valve. In vitro testing has shown the SGPV to be identical to the conven-
tional CryoLife valve in biomechanical characteristics, and histologic
staining also shows maintenance of normal valve structural elements with-
out cells.20
Statistical Methods
SPSS version 11.5 forWindows statistical software (SPSS, Inc, Chicago,
Ill) was used for all statistical analyses. Continuous data are presented as
mean  SD and range and were tested for normality with the
Kolmogorov–Smirnov test. Normal data were compared with the Student
t test, whereas the Mann–Whitney U test was used for comparisons with
nonnormally distributed data. Categoric data are presented as proportions
and compared with Fisher’s Exact Test. Adverse events, including actuarial
survival; freedom from valve-related mortality; valve explantation; reoper-
ation or reintervention; thromboembolism, thrombosis, or bleeding;
nonstructural dysfunction; valve-related failure; and endocarditis were ana-
lyzed with the Kaplan–Meier method. The survival of a patient started at the
time of pulmonary valve operation and ended at the time of death (event) or
at the last follow-up (censoring). The analysis of allograft valve survival
started at the time of implantation and ended with reoperation (event), last
follow-up, or patient death (censoring). The Tyrone–Ware test was used
to compare Kaplan–Meier curves between groups (correcting for the differ-
ences in follow-up time between the groups). Linearized occurrence rates
(LORs) were calculated for adverse events as the total number of observed
late (>30 days) events divided by the total patient-years of follow-up.
A propensity score for each patient was calculated to determine the prob-
ability of valve replacement with SGPV with separate logistic regressions
for the RVOT reconstruction and Ross populations. Variables included in
the propensity score regression model were chosen according to differences
in preoperative baseline characteristics between the conventional valve andery c February 2010
TABLE 1. Preoperative demographic data for patients undergoing Ross procedure and reconstruction of right ventricular outflow tract
Ross RVOT
SGPV CV P value SGPV CV P value
No. of patients 193 665 149 581
Age (y)
Mean  SD 30.7  6.3 28.3  16.6 .07 15.0  13.2 9.7  12.0 .0001
Median 32.4 28.4 13.4 5.2
Range 0–63.6 0–72.2 0–69.6 0–70.7
<18 y (%) 27 34 75 85
<1 y (%) 3 2 11 18
Sex (% male) 71 76 .13 62 60 .51
Valve diameter (mm)
Mean  SD 24.6  2.7 25.1  3.0 .001 21.4  4.3 21.0  4.6 .31
Range 10–30 12–30 9–29 8–31
Allograft z score (mean  SD) 0.42  1.2 1.0  1.2 .0001 0.9  1.5 1.9  1.6 .0001
Etiology (no.) .02 .0001
Congenital 123 (64%) 324 (55.2%) 64 (43%) 315 (64%)
Acquired 63 (33%) 234 (39.9%) 83 (56%) 129 (26%)
Congenital and acquired 1 19 1 50
Unknown 6 78 1 87
Previous valve replacement (no.) 22 (11%) 50 (7.5%) .10 75 (50%) 178 (30%) .0001
Aortic 22 50 18 31
Mechanical 6 16 0 3
Bioprosthesis 2 7 1 1
Allograft 8 22 2 2
Autograft NA NA 12 17
Unknown 6 5 3 8
Pulmonary NA NA 73 170
Bioprosthesis NA NA 3 27
Allograft NA NA 46 120
Unknown NA NA 24 23
RVOT, Right ventricular outflow tract reconstruction; SGPV, CryoValve SG pulmonary valve; CV, CryoValve pulmonary valve; NA, not applicable
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DSGPV groups and included patient age, patient sex, previous valve replace-
ment, congenital etiology, and allograft z score (as determined by compar-
ing the allograft valve diameter and the predicted diameter according to the
patient’s body surface area).21 The propensity score was then forced as a co-
variable into a Cox proportional hazards model for late mortality and late
valve-related failure to correct for treatment assignment.
RESULTS
Follow-up
Among the 342 SGPV recipients identified, follow-up
was complete22 (defined as follow-up after January 1,
2006, or known adverse event) for 99%. This represents
a mean follow-up of 4.0 years (range, 0–6.7), equating to
1350 patient-years, with 855 and 495 patient-years for
Ross and RVOT reconstruction groups, respectively. The
conventional valve control data follow-up was 94% com-
plete, representing a mean follow-up of 3.7 years (range,
0–6.7 patient-years), equating to 4653 patient years, with
2681 and 1954 patient-years for Ross and RVOT reconstruc-
tion groups, respectively.
Survival
In the SGPVRoss group, there were 3 early deaths (1.6%,
2 pediatric, 1 adult); none were valve related. There wereThe Journal of Thoracic and Ca4 late deaths (all adult), with 1 late death (sudden unex-
plained death) at postoperative day 51, possibly valve re-
lated because an echocardiographic examination the
previous week had shown pulmonic stenosis along with
moderate to severe tricuspid regurgitation (Table 2). Early
deaths occurred in 26 conventional valve Ross cases
(3.9%, 11 pediatric, 15 adult); 3 were valve related. An
additional 7 conventional valve Ross late deaths (3 pediatric,
4 adult) occurred, none of which were valve related. Com-
paring the SGPV subpopulation with the conventional valve
subpopulation, 5-year actuarial survivals (Table 3 and
Figure 1) were similar for the SGPV (96.9%  1.3%) and
conventional valve (94.8%  0.9%) Ross subpopulations.
There were 4 early deaths among the SGPV recipients un-
dergoing RVOT reconstruction (2.7%, 1 pediatric, 3 adults);
no early deaths were valve related. Late deaths occurred in 6
SGPV recipients undergoing RVOT reconstruction (4 pedi-
atric, 2 adult); 3 late deaths (sudden unexplained deaths)
were possibly valve related; however, there was no clinical
evidence to suggest failure of the implanted valve (Table
2). Among the conventional valve recipients undergoing
RVOT reconstruction, there were 49 early deaths (8.4%,
45 pediatric, 4 adult); 1 was valve related. There were 31rdiovascular Surgery c Volume 139, Number 2 341
TABLE 2. Reported causes of late mortality for the CryoValve SG pulmonary valve population
Procedure Time from implant (d) Age at implant (y) Previous valve surgery Description of event Valve related
Ross 153 45 No Fungal mediastinitis, tore hole in aortic graft No
Ross 577 35 No Myocardial infarction from coronary artery disease No
Ross 51 47 No Sudden unexplained death Yes
Ross 1900 27 No Cancer No
RVOT 1265 1 No Arrhythmia complications after pacemaker implant No
RVOT 389 51 Pulmonary valvotomy Sudden unexplained death Yes
RVOT 339 11 2 valve replacements Sudden unexplained death Yes
RVOT 149 0.6 No Severe tracheal bronchomalacia No
RVOT 113 29 Pulmonary valvotomy Sudden unexplained death Yes
RVOT 338 5.2 Cardiac surgery Arrhythmia-related death No
RVOT, Right ventricular outflow tract reconstruction.
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Dlate deaths among conventional valve recipients undergoing
RVOT reconstruction (26 pediatric, 5 adult), of which 6
were valve related. Overall survival after RVOT reconstruc-
tion was apparently improved (P< .01) in the SGPV recip-
ients (92.3%  2.4%) relative to the conventional valve
recipients (84.6%  1.6%), primarily because of an
increase in early mortality after conventional valve RVOT
reconstructions because late mortality LORs were compara-
ble. This observation probably reflects the earlier era of
surgery in the conventional valve cohort.
The likelihood of receiving SGPV for each patient was
determined (see Table 4 for covariables used in the model
to develop the propensity scores) and forced into the Cox
proportional hazards model for late mortality. Type of valve
replacement (SGPV or conventional valve) was not a signif-
icant predictor for mortality in the propensity-adjusted Cox
proportional hazards model for patients undergoing RVOT
reconstruction (P ¼ .29; hazard ratio [HR], 0.73; 95% con-
fidence interval, [CI] 0.3–1.8). Additionally, the propensity
score was not significant for the Cox proportional hazards
model for the RVOT reconstruction population (P ¼ .47;
HR, 0.34; 95% CI, 0.01–6.5). Because there were only 11
late deaths in the Ross cohort, propensity score–adjusted
comparison of late mortality was not attempted.TABLE 3. Actuarial freedoms from adverse events at 5 years and lineariz
ventricular outflow tract reconstruction with CryoValve SG and CryoValv
Ross
5-y freedom
from event (% ± SE) LO
Event SGPV CV SGPV
Mortality 96.9%  1.3% 94.8%  0.9% 0.47%
Valve-related failure 93.9%  1.8% 96.3%  0.8% 1.50%
Endocarditis 100%  0.0% 99.3%  0.4% 0.00%
Thromboembolism, valve
thrombosis, bleeding
98.9%  0.8% 97.1%  0.7% 0.12%
Explantation 97.0%  1.4% 96.4%  0.9% 0.46%
Reintervention 94.4%  1.7% 95.5%  0.9% 1.3%
Valve-related death 99.5%  0.5% 99.5%  0.3% 0.17%
Nonstructural valve dysfunction 100%  0.0% 99.9%  0.2% 0%
RVOT, Right ventricular outflow tract; LOR, linearized occurrence rate; SGPV, CryoValve
342 The Journal of Thoracic and Cardiovascular SurgAdverse Events
The LOR for late adverse events shows a low risk of event
occurrence with time for most events, with valve-related fail-
ure being the most commonly occurring complication (vary-
ing from 0.93% per patient-year among conventional valve
recipients undergoing the Ross procedure to 2.71% per pa-
tient-year among conventional valve recipients undergoing
RVOT reconstruction). There were no differences in event
occurrence between SGPVs and conventional valves for
both Ross and RVOT reconstruction populations. Valve-re-
lated complications during follow-up, summarized by actuar-
ial freedom from events at 5 years and LOR for late events,
are included in Table 3. Figure 1 shows theKaplan–Meier ac-
tuarial freedoms from mortality, valve explantation, and
valve-related failure in Ross and RVOT reconstruction pop-
ulations receiving SGPVs or conventional valve allografts.
Valve-Related Failure
Thirteen instances of late valve-related failure occurred in
11 SGPV recipients undergoing the Ross operation (2 pedi-
atric). The predominant mode of failure was valvular steno-
sis or conduit obstruction (12 events). Intervention was
accomplished in 6 instances with balloon treatment and by
stent placement in 1. The valve was explanted in 5 instances,ed occurrence rates for patients undergoing Ross procedure and right
e pulmonary valves
RVOT
R (%/y)
5-y freedom
from event (% ± SE) LOR (%/y)
CV SGPV CV SGPV CV
0.26% 92.3%  2.4%* 84.6%  1.6%* 1.21% 1.59%
0.93% 93.4%  2.3% 89.3%  1.6% 1.61% 2.71%
0.15% 98.3%  1.2% 99.4%  0.4% 0.20% 0.1%
0.11% 99.3%  0.7% 98.0%  0.6% 0.20% 0.05%
0.90% 97.6%  1.3%y 91.4%  0.7%y 0.81% 2.15%
0.93% 92.7%  2.4% 89.5%  1.6% 1.62% 2.71%
0% 97.8%  1.3% 98.2%  0.7% 0.60% 0.26%
0% 100%  0.0% 99.6%  0.3% 0% 0%
SG pulmonary valve; CV, CryoValve pulmonary valve. *P ¼ .009. yP ¼ .07.
ery c February 2010
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D2 of which followed a previous balloon treatment, and there
was 1 valve-related death with clinical evidence of pulmonic
stenosis. Twenty-five instances of late valve-related failure
occurred in 22 conventional valve recipients undergoing
Ross procedures, with 1 patient having a second occurrence
after intervention and 1 patient having 3 interventions. The
predominant cause of failure was also stenosis or conduit ob-
struction (21 events). There was 1 instance of insufficiency
alone and 2 of mixed stenosis and insufficiency. Calcifica-
tion of the valve (in most cases also associated with stenosis)
was observed in 6 instances; there were 3 instances of leaflet
degeneration noted at explantation. Freedoms from valve-re-
lated failure at 5 years for the Ross population were 93.9%
 1.8% in the SGPV subpopulation and 96.3%  0.8% in
the conventional valve subpopulation (Table 3 and Figure 1).
In the SGPV RVOT reconstruction subgroup, late valve-
related failure occurred in 8 instances (all but 1 pediatric).
The predominant cause of failure was stenosis of the valve
or distal pulmonary arteries (5 cases). Intervention was ac-
complished in 3 cases with balloon treatment and stenting
of the pulmonary branch arteries in 1 patient. To date,
none of these RVOT reinterventions have proceeded to ex-
plantation. There were also 4 valve explantations, 3 for se-
vere insufficiency and 1 for stenosis. Two heart transplants
occurred during follow-up in the RVOT reconstruction
group; however, these cases were not included as valve-re-
lated failures because the need for a heart transplant was
not attributed to the pulmonary valve and at the time of heart
transplant no evidence of pulmonary valve-related failure
was observed. In the conventional valve RVOT reconstruc-
tion subpopulation, 53 cases of valve-related failure oc-
curred in 48 patients, with 3 patients having a second
occurrence after intervention and 1 patient having 3 inter-
ventions. For the conventional valve RVOT reconstruction
subpopulation, the predominant cause of failure was also
stenosis (19 cases), but insufficiency was also common
(15 cases) and in 8 cases patients had mixed stenoses and in-
sufficiency. Calcification of the valve (in most cases also as-
sociated with stenosis) was observed in 15 instances; there
were 6 instances of leaflet degeneration noted at explanta-
tion, 1 pseudoaneurysm, 2 other events, and 7 cases in which
failure mode was not provided. Freedoms from valve-related
failure at 5 years for the RVOT reconstruction population
was 93.4%  2.3% in the SGPV subpopulation and
89.3%  1.6% in the conventional valve subpopulation
(Table 3 and Figure 1).
The propensity score for receiving SGPV was forced into
the Cox proportional hazards model for valve-related failure
separately for Ross and RVOT reconstruction populations.
Type of valve replacement (SGPV or conventional valve)
was not a significant predictor for late valve-related failure
in the propensity-adjusted Cox proportional hazards model
for the Ross population (P ¼ .25; HR, 1.6; 95% CI; 0.7–The Journal of Thoracic and Ca3.5) or the RVOT reconstruction population (P ¼ .27; HR,
0.64; 95% CI, 0.3–1.4). Additionally, the propensity score
was not significant for either the Ross population (P ¼
.53; HR, 2.5; 95% CI, 0.1–44.6) or the RVOT reconstruc-
tion population (P ¼ .75; HR, 0.75; 95% CI, 0.2–14.5) in
the Cox proportional hazards model.Other Events
One case of endocarditis was reported among the SGPV
recipients, that of a patient at day 1044 after RVOT recon-
struction. Late thromboembolic or bleeding events occurred
in 2 SGPV recipients: 1 patient displayed 2 echo densemasses
on the allograft at day 124 after the Ross operation, which
resolved following anticoagulation, and 1 patient had pulmo-
nary embolism as a consequence of RVOT aneurysm at day
1736 after RVOT reconstruction (this patient was awaiting
surgery at last follow-up). Nonstructural valve dysfunction
was not observed among the SGPV recipients. Among the
conventional valve recipients, there were 3 instances of non-
structural valve dysfunction, all of which were suture-line de-
hiscences occurring early after implantation.Hemodynamic Function
Echocardiographic data at last follow-up were available
from 162 SGPV patients undergoing the Ross procedure
(90% of population still at risk) at a mean follow-up of
3.9 years (range, 1–6.6 years) and 115 SGPV recipients un-
dergoing RVOT reconstruction (87% of population still at
risk) at a mean follow-up of 3.2 years (range, 1–6.4 years).
Peak gradients and pulmonary insufficiency grades were
compared with data available from 368 conventional valve
recipients undergoing the Ross procedure (61% of popula-
tion still at risk) at a mean follow-up of 3.7 years (range,
1–6.2 years) and 188 conventional valve recipients undergo-
ing RVOT reconstruction (41% of population still at risk) at
a mean follow-up of 3.6 years (range, 1–6.0 years).
The mean peak pulmonary gradient was 19.0  17.2 mm
Hg for 151 SGPV recipients undergoing the Ross procedure
versus 21.7 16.7 mmHg for 323 conventional valve recip-
ients (P<.002; Figure 2). In the RVOT reconstruction pop-
ulation, however, mean peak gradient did not differ between
110 SGPV recipients (22.9 17.4 mmHg) and 168 conven-
tional valve recipients (22.2  15.3 mm Hg; Figure 2). Ad-
ditionally, pulmonary insufficiency grades were
significantly lower in SGPV recipients relative to conven-
tional valve recipients undergoing both Ross procedures
(P< .01) and RVOT reconstruction (P< .01; Figure 3).DISCUSSION
The SGPV provides patients undergoing Ross procedures
and RVOT reconstruction with a functional and durable so-
lution at 4-year follow-up, with low occurrence rates of en-
docarditis and other valve-related complications. Valve typerdiovascular Surgery c Volume 139, Number 2 343
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tor for valve-related failure in the propensity-adjusted anal-
ysis. Five-year freedoms from valve-related failure were not
significantly different when comparing the SGPV with the
conventionally processed valve. Echocardiographic parame-
ters, however, suggest that valve performance after 4 years
was improved with SGPV. Peak gradients in the Ross
SGPV subpopulation were statistically lower, although it re-
mains to be determined whether this statistical improvement
is clinically relevant. Improvement in valve competence af-
ter both Ross procedure and RVOT reconstruction was ob-
served among SGPV recipients relative to conventional
valve recipients.Historical Reports of Allograft Durability
In the 1960s and mid 1970s, the use of allografts for aortic
and pulmonary valve replacement was hypothesized to be
associated with superior durability relative to second-gener-
ation bioprostheses. With time, the various methods for allo-
graft valve processing were observed to have divergent
outcomes, with poor results observed when most steriliza-
tion methods were used (irradiation, ethylene oxide treat-
ment, long-term maintenance in antibiotics); however,
long-term outcomes with fresh and cryopreserved valves
were observed to be superior.4,23 It was speculated that
maintenance of viability was therefore important in the
long-term function of allograft valves. In the last 2 decades,
allograft processing around the world has primarily been ac-
complished by cryopreservation to maintain a degree of graft
viability and allow for long periods of storage. Structural
failure has continued to be an issue with allografts, however,
leading to much speculation that failure may be partly re-
lated to the persistence of cellularity and the resulting immu-
nogenicity of the grafts.8-11,24
The 94% 5-year freedom from valve-related failure in the
Ross SGPV subpopulation is comparable to literature re-
ports of 92% to 96% at 5 to 7 years after the Ross operation
among patients with conventionally processed allo-
grafts.1,3,6,25
Freedom from valve-related failure with conventionally
processed allograft valves in RVOT reconstruction has
been reported as 60% to 74% at 5 years.7,26 Patients in these
published series were primarily younger (mean ages of 3.6
and 4.3 years) than in this series. Another series reporting
on 297 patients undergoing RVOT reconstruction with
mean age of 18 years showed freedom from valve-related
events of 80% at 8 years.27 Our current results with 93%
freedom from valve-related failure at 5 years amongFIGURE 1. Actuarial freedoms from mortality, valve explantation, and valve-
tation (C and D), and valve-related failure (E and F) for patients undergoing Ros
struction (B, D, and F) with CryoValve SG pulmonary valves (SGPV) or convent
risk is provided yearly.
The Journal of Thoracic and CaSGPV recipients are encouraging; the older mean age of
the SGPV recipients (15 years) could be a factor contributing
to these positive results, but 50% of patients in this RVOT
reconstruction series had received the SGPV after a previous
failed graft and thus could also be argued to present a more
difficult challenge.
The SynerGraft process has been shown to provide effec-
tive reduction in antigenic donor cells and cell remnants.20,28
Maintenance of the structural integrity of the resulting decel-
lularized matrix was previously only surmised from avail-
able in vitro data and relatively short-term if promising
clinical data.13-16,20,29,30 This study provides additional evi-
dence, with implantation time now approaching 7 years, that
this process effectively maintains structural integrity of the
valve, with possible improvements in hemodynamic perfor-
mance. An extended follow-up of the SGPV group will help
determine whether the reduced immunogenicity and im-
proved hemodynamics will lead to superior longer-term du-
rability.
Other Valve-Related Complications
Allograft endocarditis was uncommon among the SGPV
recipients, with only 1 case among those undergoing
RVOT reconstruction. This underlines the resistance of the
SGPV to infection and is comparable to other reports.1,2,4-
6,27 Furthermore, the absence of nonstructural valve-related
failure and extremely low occurrence rates of thromboem-
bolic and bleeding complications illustrate the benefits that
the SGPV has in common with the conventional
valve.1,4,6,27
Comparison with Conventional Valve
We compared outcomes after SGPV implantation with
those of a historical cohort of patients who received conven-
tional pulmonary valves to assess whether the SynerGraft
treatment had any effect on valve performance. Although
there were differences between the 2 populations with regard
to both patient characteristics and era of operation (primarily
in the RVOT reconstruction groups) late survival was com-
parable for the Ross and the RVOT reconstruction popula-
tions. Importantly, the propensity-adjusted late survival
was equivalent for conventional and SGPV recipients under-
going RVOT reconstruction. Freedom from explantation
was also comparable for the SGPV and conventional valve
recipients undergoing the Ross procedure; however, SGPV
tended to reduce explantation rate in the RVOT reconstruc-
tion population, possibly because of the differences in pa-
tient age and disease etiology. Of note, the incidence ofrelated failure. Actuarial freedoms from mortality (A and B), valve explan-
s procedure (A, C, and E) and right ventricular outflow tract (RVOT) recon-
ionally processed CryoValve pulmonary valves (CV).Number of patients at
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TABLE 4. Predictors of selection for CryoValve SG pulmonary valve
Ross RVOT
Predictor OR 95% CI P value OR 95% CI P value
Previous aortic or pulmonary valve replacement 2.4 1.3–4.4 .004 2.1 1.4–3.1 .001
Age 1.0 0.9–1.0 .940 1.0 0.9–1.0 .299
Female sex 1.8 1.2–2.6 .004 1.1 0.7–1.6 .688
Allograft z score 0.6 0.5–0.7 .0001 0.6 0.5–0.7 .621
Congenital etiology 2.5 1.7–3.6 .0001 1.0 0.7–1.5 .958
RVOT, Right ventricular outflow tract reconstruction; OR, odds ratio; CI, confidence interval.
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Dvalve calcification appears to be reduced among the SGPV
recipients. At explantation, only 1 SGPV was reported as
calcified (11% of the valve-related explantations, 0.3% of
the total population), compared with 21 cases among the
conventional valve recipients (35% of the total valve-related
explantations, 1.6% of the total population).
Valve function, as assessed by peak pulmonary gradients
and insufficiency, was improved at last follow-up with the
SGPV relative to the conventional valve. SGPV recipients
undergoing Ross procedures showed lower peak gradients
and improved competence at similar follow-up when com-
pared with conventional valve recipients. There was no dif-
ference in peak gradients for the RVOT reconstruction
cohort, but SGPV recipients did demonstrate improved
valve competence, although the older age of the SGPV pop-
ulation could be a factor in this result. Although the 4-year
hemodynamic performance in the SGPV recipients mayFIGURE 2. Peak gradient at last follow-up. Proportion of patients under-
going Ross procedure or right ventricular outflow tract (RVOT) reconstruc-
tion with CryoValve SG pulmonary valve (SGPV) or conventionally
processed CryoValve (CV) with peak pulmonary gradients 0 to 9, 10 to
29, 30 to 49 or at least 50 mm Hg. Peak pulmonary gradient was measured
at mean follow-up of 3.9 1.4 years for CryoValve SG pulmonary valves in
Ross procedure, 4.1  1.5 years for conventional CryoValves in Ross pro-
cedure, 3.3  1.4 years for CryoValve SG pulmonary valves in right ven-
tricular outflow tract reconstruction, and 3.7  1.4 years for conventional
CryoValves in right ventricular outflow tract reconstruction. Number of
patients with peak gradient measured is shown below each bar.
346 The Journal of Thoracic and Cardiovascular Surghave been improved, the propensity-adjusted analysis for
valve-related failure did not identify valve type as a risk fac-
tor for failure for patients undergoing either the Ross proce-
dure or RVOT reconstruction.
This report is consistent with short-term data reported on
the SGPV by several centers. Tavakkol and colleagues29
compared 26 SGPV recipients with 26 historical age-
matched recipients of conventionally processed valves. The
mean age of the SGPV group was 61 months. At a mean
follow-up of 19 months, the SGPV group showed signifi-
cantly less regurgitation than the conventional valve group.
Although the mean peak gradient was low in both groups,
it was statistically lower in the SGPV group (7.6 mm
Hg vs 14.6 mmHg). Hawkins and colleagues16 also reported
echocardiographic follow-up at a mean of 8 months for
8 SGPV valves versus 8 conventionally processed valves
for RVOT reconstruction. The average peak gradient for
the SGPV was 13 mm Hg, as compared with 24 mm Hg
for the conventional valve.
Bechtel, Stierle, and Sievers31 have recently published
their Ross series with SGPVs and compared these grafts
with conventional pulmonary allografts. At a mean of 52
months (maximum 71 months), they have had no reopera-
tions in their SGPV recipients and state that this provides ev-
idence for durability of the SGPV. Mean peak gradients
were slightly but statistically higher in their SGPV recipients
than among their control patients, but the increase occurred
primarily within the first 6 months of implantation and has
been stable since. There was no pulmonary insufficiency ob-
served in this series of SGPV recipients undergoing the Ross
procedure, supporting our observation of reduced pulmo-
nary insufficiency with the SGPV.LIMITATIONS
SGPV valve performance was compared with a historical
retrospective conventional valve cohort. Differences in era
of implantation could have influenced the results of the
study, because the conventional valve cohort was from an
earlier era than the SGPV cohort. This factor could not be
addressed by the multivariate analysis, because the eras of
implantation did not have sufficient overlap, so this differ-
ence is still an outstanding limitation of the study. There
were significant differences in patient ages between theery c February 2010
FIGURE 3. Pulmonary insufficiency grade at last follow-up. Pulmonary
insufficiency grades of patients undergoing Ross procedure or right ventric-
ular outflow tract (RVOT) reconstruction with CryoValve SG pulmonary
valves (SGPV) or conventionally processed CryoValves (CV). Pulmonary
insufficiency grade was measured at mean follow-up of 4.1  1.4 years
for CryoValve SG pulmonary valves in Ross procedure, 3.7  1.5 years
for conventional CryoValves in Ross procedure, 3.3  1.3 years for Cryo-
Valve SG pulmonary valves in right ventricular outflow tract reconstruction,
and 3.7  1.5 years for conventional CryoValves in right ventricular out-
flow tract reconstruction. Number of patients with pulmonary insufficiency
grade measured is shown below each bar.
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Dtwo RVOT reconstruction subpopulations, with the SGPV
recipients being older than the conventional valve recipients.
The propensity-adjusted model for valve-related failure and
survival did not, however, indicate a difference in valve type
while accounting for the difference in age. Because this was
a purely retrospective study, the cardiologic evaluations by
the patient physicians were accepted, and there was no stan-
dard protocol for reporting echocardiographic data. Longer
follow-up is needed to determine whether the reduced allo-
antibody response of the SGPV valve and improvements in
hemodynamic performance persist and whether they will
translate into increased valve durability.
CONCLUSIONS
This multicenter, retrospective cohort study of 342 con-
secutive patients receiving the SGPV supports earlier evi-
dence that the SGPV is an appropriate graft for patients
requiring pulmonary valve replacement or reconstruction.
Overall, at a mean of 4 years the SGPV appears to be safe
and have at least comparable, if not improved, hemody-
namic performance. A compelling reason for use of the Syn-
erGraft-processed valve is the possibility that reduced
cellular content provides an immunologic benefit to the pa-
tient. Whether this benefit translates to greater valve longev-
ity or better long-term function remains to be demonstrated.
Additional long-term follow-up of these patients is ongoing
and may answer some of the remaining questions regarding
potential clinical benefits of the SGPV.The Journal of Thoracic and CaReferences
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